Literature DB >> 19117696

Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas.

Robert J Myerson1, Michael C Garofalo, Issam El Naqa, Ross A Abrams, Aditya Apte, Walter R Bosch, Prajnan Das, Leonard L Gunderson, Theodore S Hong, J J John Kim, Christopher G Willett, Lisa A Kachnic.   

Abstract

PURPOSE: To develop a Radiation Therapy Oncology Group (RTOG) atlas of the elective clinical target volume (CTV) definitions to be used for planning pelvic intensity-modulated radiotherapy (IMRT) for anal and rectal cancers. METHODS AND MATERIALS: The Gastrointestinal Committee of the RTOG established a task group (the nine physician co-authors) to develop this atlas. They responded to a questionnaire concerning three elective CTVs (CTVA: internal iliac, presacral, and perirectal nodal regions for both anal and rectal case planning; CTVB: external iliac nodal region for anal case planning and for selected rectal cases; CTVC: inguinal nodal region for anal case planning and for select rectal cases), and to outline these areas on individual computed tomographic images. The imaging files were shared via the Advanced Technology Consortium. A program developed by one of the co-authors (I.E.N.) used binomial maximum-likelihood estimates to generate a 95% group consensus contour. The computer-estimated consensus contours were then reviewed by the group and modified to provide a final contouring consensus atlas.
RESULTS: The panel achieved consensus CTV definitions to be used as guidelines for the adjuvant therapy of rectal cancer and definitive therapy for anal cancer. The most important difference from similar atlases for gynecologic or genitourinary cancer is mesorectal coverage. Detailed target volume contouring guidelines and images are discussed.
CONCLUSION: This report serves as a template for the definition of the elective CTVs to be used in IMRT planning for anal and rectal cancers, as part of prospective RTOG trials.

Entities:  

Mesh:

Year:  2008        PMID: 19117696      PMCID: PMC2709288          DOI: 10.1016/j.ijrobp.2008.08.070

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Oncology Group study.

Authors:  J A Martenson; S R Lipsitz; H Wagner; E H Kaplan; L A Otteman; L M Schuchter; E G Mansour; M S Talamonti; A B Benson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-07-01       Impact factor: 7.038

2.  Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer.

Authors:  Wim Duthoy; Werner De Gersem; Koen Vergote; Tom Boterberg; Cristina Derie; Peter Smeets; Carlos De Wagter; Wilfried De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

3.  Chemotherapy with preoperative radiotherapy in rectal cancer.

Authors:  Jean-François Bosset; Laurence Collette; Gilles Calais; Laurent Mineur; Philippe Maingon; Ljiljana Radosevic-Jelic; Alain Daban; Etienne Bardet; Alexander Beny; Jean-Claude Ollier
Journal:  N Engl J Med       Date:  2006-09-14       Impact factor: 91.245

4.  Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning.

Authors:  Lye Mun Tho; Martin Glegg; Jennifer Paterson; Christina Yap; Alice MacLeod; Marie McCabe; Alexander C McDonald
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-31       Impact factor: 7.038

5.  Risk of pelvic fractures in older women following pelvic irradiation.

Authors:  Nancy N Baxter; Elizabeth B Habermann; Joel E Tepper; Sara B Durham; Beth A Virnig
Journal:  JAMA       Date:  2005-11-23       Impact factor: 56.272

6.  Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08.

Authors:  M John; T Pajak; M Flam; J Hoffman; A Markoe; H Wolkov; K Paris
Journal:  Cancer J Sci Am       Date:  1996 Jul-Aug

7.  Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

Authors:  Jean-Pierre Gérard; Thierry Conroy; Franck Bonnetain; Olivier Bouché; Olivier Chapet; Marie-Thérèse Closon-Dejardin; Michel Untereiner; Bernard Leduc; Eric Francois; Jean Maurel; Jean-François Seitz; Bruno Buecher; Rémy Mackiewicz; Michel Ducreux; Laurent Bedenne
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

8.  The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.

Authors:  Kathy L Baglan; Robert C Frazier; Di Yan; Raywin R Huang; Alvaro A Martinez; John M Robertson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-01-01       Impact factor: 7.038

9.  Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.

Authors:  Gary M Freedman; Neal J Meropol; Elin R Sigurdson; John Hoffman; Elaine Callahan; Robert Price; Jonathan Cheng; Steve Cohen; Nancy Lewis; Deborah Watkins-Bruner; André Rogatko; Andre Konski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-01       Impact factor: 7.038

10.  A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation.

Authors:  M J Gallagher; H D Brereton; R A Rostock; J M Zero; D A Zekoski; L F Poyss; M P Richter; M M Kligerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-09       Impact factor: 7.038

View more
  134 in total

1.  Dosimetric planning study for the prevention of anal complications after post-operative whole pelvic radiotherapy in cervical cancer patients with hemorrhoids.

Authors:  J G Baek; E C Kim; S K Kim; H Jang
Journal:  Br J Radiol       Date:  2015-09-23       Impact factor: 3.039

2.  A treatment planning study of prone vs. supine positions for locally advanced rectal carcinoma : Comparison of 3‑dimensional conformal radiotherapy, tomotherapy, volumetric modulated arc therapy, and intensity-modulated radiotherapy.

Authors:  Sergiu Scobioala; Christopher Kittel; Philipp Niermann; Heidi Wolters; Katharina Helene Susek; Uwe Haverkamp; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2018-05-31       Impact factor: 3.621

3.  Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease.

Authors:  Amar U Kishan; Justin C Voog; Jonathan Wiseman; Ryan R Cook; Marek Ancukiewicz; Percy Lee; David P Ryan; Jeffrey W Clark; David L Berger; James C Cusack; Jennifer Y Wo; Theodore S Hong
Journal:  Br J Radiol       Date:  2017-06-14       Impact factor: 3.039

4.  Bone marrow tolerance during postoperative chemotherapy in colorectal carcinomas.

Authors:  Neil B Newman; Rebecca A Moss; Nell Maloney-Patel; Kristen Donohue; Teresa V Brown; Michael J Nissenblatt; Shou-En Lu; Salma K Jabbour
Journal:  J Gastrointest Oncol       Date:  2017-06

Review 5.  Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Authors:  Guillaume Klausner; Eivind Blais; Raphaël Jumeau; Julian Biau; Mailys de Meric de Bellefon; Mahmut Ozsahin; Thomas Zilli; Raymond Miralbell; Juliette Thariat; Idriss Troussier
Journal:  Med Oncol       Date:  2018-08-20       Impact factor: 3.064

Review 6.  Locally advanced gastroesophageal junction tumor: a treatment dilemma.

Authors:  Noman Ashraf; Sarah Hoffe; Richard Kim
Journal:  Oncologist       Date:  2015-01-05

7.  Quantitative assessment of target delineation variability for thymic cancers: Agreement evaluation of a prospective segmentation challenge.

Authors:  Emma Holliday; Clifton D Fuller; Jayashree Kalpathy-Cramer; Daniel Gomez; Andreas Rimner; Ying Li; Suresh Senan; Lynn D Wilson; Jehee Choi; Ritsuko Komaki; Charles R Thomas
Journal:  J Radiat Oncol       Date:  2015-11-03

8.  Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.

Authors:  M S Agarwal; K E Hitchcock; C G Morris; T J George; W M Mendenhall; R A Zlotecki
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

9.  Consequences of anorectal cancer atlas implementation in the cooperative group setting: radiobiologic analysis of a prospective randomized in silico target delineation study.

Authors:  Panayiotis Mavroidis; Drosoula Giantsoudis; Musaddiq J Awan; Jasper Nijkamp; Coen R N Rasch; Joop C Duppen; Charles R Thomas; Paul Okunieff; William E Jones; Lisa A Kachnic; Niko Papanikolaou; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-07-01       Impact factor: 6.280

10.  A fast radiotherapy paradigm for anal cancer with volumetric modulated arc therapy (VMAT).

Authors:  Florian Stieler; Dirk Wolff; Frank Lohr; Volker Steil; Yasser Abo-Madyan; Friedlieb Lorenz; Frederik Wenz; Sabine Mai
Journal:  Radiat Oncol       Date:  2009-10-25       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.